Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022
CONCLUSION: Findings from our analysis of reports to CAEFISS and CVD following vaccination with SIV are consistent with the known safety profile of SIVs distributed during the 2021/2022 influenza season. The majority of reports were non-serious with the most common AEFI symptoms occurring at the vaccination site or systemic symptoms that were self-limiting. The majority of vaccination error reports involved the administration of the vaccine at an inappropriate site, although no serious AEFIs were reported.PMID:38655243 | PMC:PMC11037881 | DOI:10.14745/ccdr.v50i12a02 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - April 24, 2024 Category: Infectious Diseases Authors: Elissa Giang Yuhui Xu Thivya Naganathan Natalia Abraham Marie-Th érèse Bawolak Battouli Said Salim Ashley Weeks Amanda Shaw Susanna Ogunnaike-Cooke Source Type: research
Molecules, Vol. 29, Pages 1945: Oxymatrine Modulation of TLR3 Signaling: A Dual-Action Mechanism for H9N2 Avian Influenza Virus Defense and Immune Regulation
This study investigated the H9N2 AIV antiviral properties of Oxymatrine (OMT), a compound derived from traditional Chinese medicine, particularly focusing on its interaction with pulmonary microvascular endothelial cells (PMVECs). Employing an array of in vitro assays, including 50% tissue culture infectious dose, Cell Counting Kit-8, reverse transcription-quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blot, we systematically elucidated the multifaceted effects of OMT. OMT dose-dependently inhibited critical antiviral proteins (PKR and Mx1) and modulated the expression of type I inte...
Source: Molecules - April 24, 2024 Category: Chemistry Authors: Yan Zhi Xinping Zhao Zhenyi Liu Guoyu Shen Taiming Zhang Tao Zhang Ge Hu Tags: Article Source Type: research
Pharmacy-Based Influenza Vaccination: A Study of Patient Acceptance in Romania
(Source: Risk Management and Healthcare Policy)
Source: Risk Management and Healthcare Policy - April 23, 2024 Category: Health Management Tags: Risk Management and Healthcare Policy Source Type: research
Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -...
Source: Journal of Korean Medical Science - April 23, 2024 Category: Biomedical Science Authors: Yu Jung Choi Jang Wook Sohn Won Suk Choi Seong-Heon Wie Jacob Lee Jin-Soo Lee Hye Won Jeong Joong Sik Eom Eliel Nham Hye Seong Jin Gu Yoon Ji Yun Noh Joon Young Song Hee Jin Cheong Woo Joo Kim Source Type: research
The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from Several European Countries and Israel
Expert Rev Respir Med. 2024 Apr 23. doi: 10.1080/17476348.2024.2340470. Online ahead of print.ABSTRACTINTRODUCTION: The Raise Awareness of Influenza Strategies in Europe (RAISE) group gathered information about the healthcare burden of influenza (hospitalizations, intensive care unit [ICU] admissions, and excess deaths), surveillance systems, and the vaccine coverage rate (VCR) in older adults in 18 European countries and Israel.AREAS COVERED: Published medical literature and official medical documentation on the influenza disease burden in the participating countries were reviewed from 2010/11 until the 2022/23 influenza ...
Source: Expert Review of Respiratory Medicine - April 23, 2024 Category: Respiratory Medicine Authors: George Kassianos Jean-Marie Cohen Rok Civljak Nadav Davidovitch Oana Falup Pecurariu Filipe Froes Andrei Galev Inga Ivaskeviciene Kadri K õivumägi Zuzana Kristufkova Ernest Kuchar Jan Kyncl Helena C Maltezou Milo š Marković Aneta Nitsch-Osuch Raul Ort Source Type: research
Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -...
Source: J Korean Med Sci - April 23, 2024 Category: General Medicine Authors: Yu Jung Choi Jang Wook Sohn Won Suk Choi Seong-Heon Wie Jacob Lee Jin-Soo Lee Hye Won Jeong Joong Sik Eom Eliel Nham Hye Seong Jin Gu Yoon Ji Yun Noh Joon Young Song Hee Jin Cheong Woo Joo Kim Source Type: research
The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from Several European Countries and Israel
Expert Rev Respir Med. 2024 Apr 23. doi: 10.1080/17476348.2024.2340470. Online ahead of print.ABSTRACTINTRODUCTION: The Raise Awareness of Influenza Strategies in Europe (RAISE) group gathered information about the healthcare burden of influenza (hospitalizations, intensive care unit [ICU] admissions, and excess deaths), surveillance systems, and the vaccine coverage rate (VCR) in older adults in 18 European countries and Israel.AREAS COVERED: Published medical literature and official medical documentation on the influenza disease burden in the participating countries were reviewed from 2010/11 until the 2022/23 influenza ...
Source: Respiratory Care - April 23, 2024 Category: Respiratory Medicine Authors: George Kassianos Jean-Marie Cohen Rok Civljak Nadav Davidovitch Oana Falup Pecurariu Filipe Froes Andrei Galev Inga Ivaskeviciene Kadri K õivumägi Zuzana Kristufkova Ernest Kuchar Jan Kyncl Helena C Maltezou Milo š Marković Aneta Nitsch-Osuch Raul Ort Source Type: research
Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -...
Source: Journal of Korean Medical Science - April 23, 2024 Category: Biomedical Science Authors: Yu Jung Choi Jang Wook Sohn Won Suk Choi Seong-Heon Wie Jacob Lee Jin-Soo Lee Hye Won Jeong Joong Sik Eom Eliel Nham Hye Seong Jin Gu Yoon Ji Yun Noh Joon Young Song Hee Jin Cheong Woo Joo Kim Source Type: research
The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from Several European Countries and Israel
Expert Rev Respir Med. 2024 Apr 23. doi: 10.1080/17476348.2024.2340470. Online ahead of print.ABSTRACTINTRODUCTION: The Raise Awareness of Influenza Strategies in Europe (RAISE) group gathered information about the healthcare burden of influenza (hospitalizations, intensive care unit [ICU] admissions, and excess deaths), surveillance systems, and the vaccine coverage rate (VCR) in older adults in 18 European countries and Israel.AREAS COVERED: Published medical literature and official medical documentation on the influenza disease burden in the participating countries were reviewed from 2010/11 until the 2022/23 influenza ...
Source: Expert Review of Respiratory Medicine - April 23, 2024 Category: Respiratory Medicine Authors: George Kassianos Jean-Marie Cohen Rok Civljak Nadav Davidovitch Oana Falup Pecurariu Filipe Froes Andrei Galev Inga Ivaskeviciene Kadri K õivumägi Zuzana Kristufkova Ernest Kuchar Jan Kyncl Helena C Maltezou Milo š Marković Aneta Nitsch-Osuch Raul Ort Source Type: research
Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -...
Source: J Korean Med Sci - April 23, 2024 Category: General Medicine Authors: Yu Jung Choi Jang Wook Sohn Won Suk Choi Seong-Heon Wie Jacob Lee Jin-Soo Lee Hye Won Jeong Joong Sik Eom Eliel Nham Hye Seong Jin Gu Yoon Ji Yun Noh Joon Young Song Hee Jin Cheong Woo Joo Kim Source Type: research
The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from Several European Countries and Israel
Expert Rev Respir Med. 2024 Apr 23. doi: 10.1080/17476348.2024.2340470. Online ahead of print.ABSTRACTINTRODUCTION: The Raise Awareness of Influenza Strategies in Europe (RAISE) group gathered information about the healthcare burden of influenza (hospitalizations, intensive care unit [ICU] admissions, and excess deaths), surveillance systems, and the vaccine coverage rate (VCR) in older adults in 18 European countries and Israel.AREAS COVERED: Published medical literature and official medical documentation on the influenza disease burden in the participating countries were reviewed from 2010/11 until the 2022/23 influenza ...
Source: Respiratory Care - April 23, 2024 Category: Respiratory Medicine Authors: George Kassianos Jean-Marie Cohen Rok Civljak Nadav Davidovitch Oana Falup Pecurariu Filipe Froes Andrei Galev Inga Ivaskeviciene Kadri K õivumägi Zuzana Kristufkova Ernest Kuchar Jan Kyncl Helena C Maltezou Milo š Marković Aneta Nitsch-Osuch Raul Ort Source Type: research
Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -...
Source: Journal of Korean Medical Science - April 23, 2024 Category: Biomedical Science Authors: Yu Jung Choi Jang Wook Sohn Won Suk Choi Seong-Heon Wie Jacob Lee Jin-Soo Lee Hye Won Jeong Joong Sik Eom Eliel Nham Hye Seong Jin Gu Yoon Ji Yun Noh Joon Young Song Hee Jin Cheong Woo Joo Kim Source Type: research
The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from Several European Countries and Israel
Expert Rev Respir Med. 2024 Apr 23. doi: 10.1080/17476348.2024.2340470. Online ahead of print.ABSTRACTINTRODUCTION: The Raise Awareness of Influenza Strategies in Europe (RAISE) group gathered information about the healthcare burden of influenza (hospitalizations, intensive care unit [ICU] admissions, and excess deaths), surveillance systems, and the vaccine coverage rate (VCR) in older adults in 18 European countries and Israel.AREAS COVERED: Published medical literature and official medical documentation on the influenza disease burden in the participating countries were reviewed from 2010/11 until the 2022/23 influenza ...
Source: Expert Review of Respiratory Medicine - April 23, 2024 Category: Respiratory Medicine Authors: George Kassianos Jean-Marie Cohen Rok Civljak Nadav Davidovitch Oana Falup Pecurariu Filipe Froes Andrei Galev Inga Ivaskeviciene Kadri K õivumägi Zuzana Kristufkova Ernest Kuchar Jan Kyncl Helena C Maltezou Milo š Marković Aneta Nitsch-Osuch Raul Ort Source Type: research
Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea
In this study, we aimed to estimate the interim vaccine effectiveness (VE) of the influenza vaccination to prevent influenza during the early season. From November 1, 2023, to December 31, 2023, we enrolled 2,632 subjects with influenza-like illness from eight hospitals participating in hospital-based influenza morbidity and mortality surveillance. A retrospective test-negative case-control study was conducted to estimate the VE. The results showed an adjusted VE of 22.5% (95% confidence interval [CI], 6.6 to 35.8) for the total population. The adjusted VE was 22.3% (95% CI, 6.1 to 35.7) for influenza A and 9.4% (95% CI, -...
Source: J Korean Med Sci - April 23, 2024 Category: General Medicine Authors: Yu Jung Choi Jang Wook Sohn Won Suk Choi Seong-Heon Wie Jacob Lee Jin-Soo Lee Hye Won Jeong Joong Sik Eom Eliel Nham Hye Seong Jin Gu Yoon Ji Yun Noh Joon Young Song Hee Jin Cheong Woo Joo Kim Source Type: research
